Changes in Beneficial Ownership · 4
OS Therapies Incorporated
OSTXNYSE_AMERICANEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-22
- Issuer
- OS Therapies Inc
- Issuer CIK
- 0001795091
- Trading symbol
- OSTX
Reporting owner 1
- Name
- Francis Knuettel II
- Reporting owner CIK
- 0001433316
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- C/O OS THERAPIES INCORPORATED, 115 PULLMAN CROSSING ROAD, SUITE 103, GRASONVILLE, MD, 21638
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 20,000 | I | By Lara Knuettel Revocable Trust[F1] |
Table key
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock options (right to buy) | 1.25 | 2026-10-22 | A · Form 4 | 300,000 | A | 0 | [F2] | 2036-10-22 | Common Stock | 300,000 | 300,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The reporting person is the co-trustee of the Lara Knuettel Revocable Trust and may be deemed to beneficially own the shares of common stock held of record by such trust. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.↩ 1
- F2
- On October 22, 2026, the reporting person was granted options to purchase 300,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date.↩ 1
Signature 1
- Signed
- /s/ Francis Knuettel II
- Date
- 2026-10-30
Company context
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma and other solid tumors. The Company is the world leader in gene-edited, Listeria-based cancer immunotherapies. Herlystic™, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. Herlystic™ is designed to target two mutated extracellular epitopes and one mutated intracellular epitope of the HER2 oncogene, requiring only one of these three epitopes to be present in a tumor (or micro-metastasis) to trigger the desired immune response. Herlystic™ has received Orphan Drug Designation (ODD), Fast Track Designation (FTD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and has received ODD, FTD and Advanced Therapy Medicinal Products (ATMP) from the European Medicines Agency.